Your browser doesn't support javascript.
loading
Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma.
Thornton, M J; Williamson, H V; Westbrook, K E; Greenup, R A; Plichta, J K; Rosenberger, L H; Gupta, A M; Hyslop, T; Hwang, E S; Fayanju, O M.
Afiliação
  • Thornton MJ; Department of Surgery, Duke University Medical Center, Durham, NC, USA.
  • Williamson HV; Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
  • Westbrook KE; Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
  • Greenup RA; Department of Medicine, Duke University Medical Center, Durham, NC, USA.
  • Plichta JK; Department of Surgery, Duke University Medical Center, Durham, NC, USA.
  • Rosenberger LH; Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
  • Gupta AM; Department of Surgery, Duke University Medical Center, Durham, NC, USA.
  • Hyslop T; Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
  • Hwang ES; Department of Surgery, Duke University Medical Center, Durham, NC, USA.
  • Fayanju OM; Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
Ann Surg Oncol ; 26(10): 3166-3177, 2019 Oct.
Article em En | MEDLINE | ID: mdl-31342392
ABSTRACT

BACKGROUND:

Neoadjuvant chemotherapy (NACT) is often recommended for patients with node-positive invasive lobular carcinoma (ILC) despite unclear benefit in this largely hormone receptor-positive (HR+) group. We sought to compare overall survival (OS) between patients with node-positive ILC who received neoadjuvant endocrine therapy (NET) and those who received NACT.

METHODS:

Women with cT1-4c, cN1-3 HR+ ILC in the National Cancer Data Base (2004-2014) who underwent surgery following neoadjuvant therapy were identified. Kaplan-Meier curves and Cox proportional hazards modeling were used to estimate unadjusted and adjusted overall survival (OS), respectively.

RESULTS:

Of the 5942 patients in the cohort, 855 received NET and 5087 received NACT. NET recipients were older (70 vs. 54 years) and had more comorbidities (Charlson-Deyo score ≥ 1 21.1% vs. 11.5%), lower cT classification (cT3-4 44.2% vs. 51.0%), lower rates of mastectomy (72.5% vs. 82.2%), lower rates of pathologic complete response (0% vs. 2.5%), and lower rates of postlumpectomy (73.2% vs. 91.0%) and postmastectomy (60.0% vs. 80.8%) radiation versus NACT recipients (all p < 0.001). NACT recipients had higher unadjusted 10-year OS versus NET recipients (57.9% vs. 36.0%), but after adjustment, there was no significant difference in OS between the two groups (p = 0.10).

CONCLUSIONS:

Patients with node-positive ILC who received NET presented with smaller tumors, older age, and greater burden of comorbidities versus NACT recipients but had similar adjusted OS. While there is evidence from clinical trials supporting efficacy of NET in HR+ breast cancer, our findings suggest the need for further, histology-specific investigation regarding the optimal inclusion and sequence of endocrine therapy and chemotherapy in ILC.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Quimioterapia Adjuvante / Carcinoma Lobular / Terapia Neoadjuvante / Inibidores da Aromatase / Linfonodos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Quimioterapia Adjuvante / Carcinoma Lobular / Terapia Neoadjuvante / Inibidores da Aromatase / Linfonodos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article